Histone Deacetylases-Based Dual Inhibitors: Research Progress Focusing on Non-Small Cell Lung Cancer Therapy

Zhiguang Yang; Zihao Liu

doi:10.1039/d6md00063k

January 1, 2026RSC Medicinal Chemistry

Histone Deacetylases-Based Dual Inhibitors: Research Progress Focusing on Non-Small Cell Lung Cancer Therapy

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to explore the role of histone deacetylases in non-small cell lung cancer and the progress of dual inhibitors as a therapeutic option.
Examined the role of HDACs in NSCLC for epigenetic regulation and drug resistance.
Reviewed therapeutic strategies targeting HDACs based on recent clinical trials and research findings.
Inhibitors targeting HDACs show improved therapeutic efficacy in NSCLC treatment.
Combination treatments with dual inhibitors exhibit reduced drug resistance compared to standard therapies.

Implication

Investigates dual inhibitors targeting histone deacetylases for NSCLC therapy, suggesting potential benefits.

Abstract

Epigenetic regulation plays a pivotal role in the initiation, progression and drug resistance mechanisms of non-small cell lung cancer (NSCLC). As important epigenetic regulatory enzymes, histone deacetylases (HDACs) are aberrantly...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69f837c23ed186a73998208a https://doi.org/10.1039/d6md00063k

View at Publisher

Ask AI

Bookmark

Share

Histone Deacetylases-Based Dual Inhibitors: Research Progress Focusing on Non-Small Cell Lung Cancer Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Histone Deacetylases-Based Dual Inhibitors: Research Progress Focusing on Non-Small Cell Lung Cancer Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading